 |
(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide |
|---|---|
| Trade Name | Fk778 |
| Orphan Indication | Prevention of acute rejection following kidney, heart, and liver transplantation |
| USA Market Approval | USA |
| USA Designation Date | 2005-01-10 00:00:00 |
| Sponsor | Astellas Pharma US, Inc.;Three Parkway North;Deerfield, Illinois, 60015 |
